Drug updated on 9/4/2024
| Dosage Form | Injection (intravenous; 600 mg/6 mL) |
| Drug Class | Monoclonal antibody against B. anthracis |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Latest News
Summary
- Anthim (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- In animal models (New Zealand White Rabbits and Cynomolgus Macaques), obiltoxaximab administration resulted in higher survival rates following anthrax exposure.
- No specific effectiveness outcomes in infected human populations were provided, reflecting the ethical and practical challenges of conducting such trials.
- The study does not offer comparative data on the effectiveness of obiltoxaximab relative to other drugs or note significant differences in effectiveness across various population types or subgroups.
- In healthy human volunteers, obiltoxaximab was tolerated with a relatively low incidence of adverse events.
- The study does not mention any specific safety concerns or adverse effects in different population types or subgroups.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Anthim (obiltoxaximab) Prescribing Information. | 2019 | Therapeutics, Inc., Parsippany, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Obiltoxaximab: Adding to the treatment arsenal for bacillus anthracis infection | 2017 | The Annals of Pharmacotherapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Virginia Department of Health Anthrax: Guidance for Healthcare Providers Key Medical and Public Health Interventions after Identification of a Suspected Case. | 2023 | Virginia Department of Health |
| Use of anthrax vaccine in the united states: Recommendations of the advisory committee on immunization practices, 2019. | 2019 | Morbidity and Mortality Weekly Report- Recommendations and Reports |